Meet Dr. Steve Rose
Steve is highly respected for his expertise and tireless commitment to finding treatments and cures for vision-robbing retinal diseases.
Archive for the ‘LCA’ Category
Three weeks ago, in recounting my participation in Charity Day at Cantor Fitzgerald, I mentioned that FFB had established October as Save Your Vision Month (SYVM). Well, now it’s here, so I wanted to reiterate what SYVM is all about and how the Foundation has been preparing for it the past couple of weeks.
Read more
Argus II “Bionic Retina” Receives Recommendation for FDA Approval
Video Included:
You wouldn’t think that the ability to sort black, white and grey socks would be a big deal for a successful attorney, but when that lawyer is completely blind from retinitis pigmentosa (RP), and used a “bionic retina” to accomplish the simple task, well, that is a big deal.
Read more
As Requested: A List of Current Clinical Trials for Retinal Degenerations
Without a doubt, as chief research officer at FFB, I get more questions about clinical trials – also known as human studies – than any other topic. So, I thought it would be useful to provide a list of the major clinical trials underway right now for retinal disease treatments. Read more
Ryan Lochte, I didn’t get a chance to meet. I did, however, get a picture taken with Michael J. Fox, who was very cordial but focused most of his attention—and rightly so—on a little girl with muscular dystrophy. Now, actor Steve Buscemi is a character and a half. I was there with Leah Bartos, who’s Mrs. New York, and because I’m Mrs. World, and the two of us were wearing crowns and sashes, he took a look at us and, before a photo was snapped, said, “Wow, let me get in between these two ladies.”
Read more
Nobel Prize Winners Have Big Impact on Emerging Retinal Treatments
Video Included:
For science geeks like me, the announcement of Nobel Prize for Medicine winners is always exciting news. But this year’s two recipients are especially near and dear to my heart, because their groundbreaking work is having an enormous impact on sight-saving retinal research.
Read more